|  |  |
| --- | --- |
| **Thursday 30th November 2023** | |
| **Joint BPS-BTS Virtual Meeting on**  ***Safety Pharmacology for the 21st Century – new technologies and approaches supporting safety and predictivity within drug discovery and development*** | |
| 08:55-09:00 | ***Meeting Opening Remarks and Welcome***  Prof. Cherry Wainwright, BPS |
| ***Session 1***  Chair: Dr.Andrea Greiter-Wilke, Co-Chair: Prof. Cherry Wainwright | |
| 09:00 – 09:30 | **Advances in Safety Pharmacology for improved risk assessment and translation of cardiovascular and CNS adverse events**  Andrea Greiter-Wilke SPS Vice President Elect, Roche, Switzerland |
| 09:30 – 10:00 | **In vitro methods for seizure liability screening**  Dr Kimberley Rockley Research Fellow, Apconix, Alderley Edge, UK |
| 10:00 – 10:30 | Questions (from chat feature) and discussion panel |
| 10:30 – 11:00 | ***Coffee Break - and virtual poster session*** |
| ***Session 2***  Chair: Dr. Andrew Brown, Co-Chair: Dr. Sue Moore | |
| 11:00 – 11:30 | **Integration of multiple endpoints into the same animal model or toxicology studies**  Henke van Der Linde, Principal Scientist, Janssen Pharmaceutical Company, Berlin, Germany |
| 11:30 – 12:00 | **Use of computational approaches to identify cardiotoxicity risk**  Maxx Holmes, University of Oxford, UK |
| 12:00 – 12:30 | Questions (from chat feature) and discussion panel |
| 12:30 – 13:30 | ***Lunch Break – and virtual poster session*** |
| ***Session 3 - Oral Communications***  Chairs: Dr. Lindsey Ferrie & Prof. Ian Copple | |
| 13:30 – 13:45 | **Macrophage-mediated inflammation and expression of FABP4 in diabetic hearts: A potential molecular target in diabetic cardiomyopathy**  Sarah Alrasheed, King Saud University, Riyadh, Saudi Arabia. |
| 13:45 – 14:00 | **Utilising an ex vivo animal model to evaluate the therapeutic index of novel antiarrhythmic prodrugs**  Louise Hesketh, King’s College London, UK |
| 14:00 – 14:15 | **Possible involvement of P2X7 receptor activation in acute myocardial infarction-induced fibrotic remodeling**  Noura Almusallam, King Saud University, Riyadh, Saudi Arabia. |
| 14:15 – 14:30 | **Predicting ADC-induced haematotoxicity using a 3D human bone marrow assay**  Benedicte Recolin, Astrazeneca, UK |
| 14:30 – 14:45 | **Evaluation of the neuroprotective potential of cannabidiol and its analogues, against ethanol-induced neurotoxicity in SH-SY5Y cells**  Carolina Aparecida De Faria Almeida, UNIFAL-MG, Brazil |
| 14:45 – 15:00 | **Establishing a relationship between drug-induced adverse events and the phenotype of intended drug target in knockout mice, a Target Safety approach**  Nicholas Coltman, Apconix, UK |
| 15:00 – 15:30 | ***Tea Break – and virtual poster session*** |
| ***Session 4***  Chair: Dr. William Proctor, Co-Chair: Ass. Prof. Antonio Pena-Fernandez | |
| 15:30 – 16:00 | **Cardiotoxicity (final title to be confirmed)**  Alexandra Schaffert Institute of Medical Biochemistry, Medical University Innsbruck, Austria |
| 16:00 – 16:30 | **Nonclinical Safety Considerations for Discovery and Development of Targeted Protein Degraders**  Dr. William Proctor, GlaxoSmithKline, USA |
| 16:30 – 17:00 | Questions (from chat feature) and discussion panel |
| 17:00 – 17:05 | ***Close of Meeting Remarks***  *Dr. Lesley Reeve, BTS* |